Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease

Movement Disorders

Volumn 22, Issue 4, 2007, Pages 483-489

  Barone, Paolo ^a   Lamb, Janice ^b   Ellis, Amanda ^b   Clarke, Zoe ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Advanced Parkinson's disease; Dopamine agonist; Levodopa adjunctive; Ropinirole; Sumanirole

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; PLACEBO; ROPINIROLE; SELEGILINE; SUMANIROLE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION;

ADULT; BENZIMIDAZOLES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34247211599     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21191     Document Type: Article

References (22)

1. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003;20:847-855.
2. Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003;250:90-96.
3. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease - an evidence-based review - report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
4. Olanow CW, Watts RL, Roller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl. 5):S1-S88.
5. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
6. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000;342:1484-1491.
7. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-1598.
8. Bracco F, Battaglia A, Chouza C, et al., PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;18:733-746.
9. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
10. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993;307:469-472.
11. Ward CD, Thompson J, Humby MD. Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment. J Neurol Neurosurg Psychiatry 1987;50:1706-1707.
12. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003;26:109-111.
13. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003;26:439-444.
14. Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005;62:1242-1248.
15. Lambert D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging 2000;16:55-65.
16. Happe S, Berger K, FAQT study investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease - a prospective study. J Neurol 2001;248:1062-1067.
17. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinon disease. Arch Neurol 2005;62:1377-1381.
18. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
19. Heier RF, Dolak LA, Duncan JN, et al. Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5- amine and its metabolites. J Med Chem 1997;40:639-646.
20. 2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J Pharmacol Exp Ther 2005;314:1248-1256.
21. Stephenson DT, Meglasson MD, Connell MA, Childs MA, Hajos-Korcsok E, Emborg ME. The effects of a selective dopamine D2 receptor agonist on behavorial and pathologic outcome in MPTP-treated squirrel monkeys. J Pharmacol Exp Ther 2005;314:1257-1266.
22. Stacy MA. Dopamine agonists. In: Pahwa R, Lyons KE, Roller WC, editors. Handbook of Parkinson's Disease, 3rd ed. New York: Marcel Dekker; 2003. p 407-423.